Prodromal Dementia With Lewy Bodies: Evolution of Symptoms and Predictors of Dementia Onset.


Journal

Journal of geriatric psychiatry and neurology
ISSN: 0891-9887
Titre abrégé: J Geriatr Psychiatry Neurol
Pays: United States
ID NLM: 8805645

Informations de publication

Date de publication:
07 2022
Historique:
pubmed: 12 6 2021
medline: 22 6 2022
entrez: 11 6 2021
Statut: ppublish

Résumé

Research criteria for prodromal dementia with Lewy bodies (DLB) were published in 2020, but little is known regarding prodromal DLB in clinical settings. We identified non-demented participants without neurodegenerative disease from the National Alzheimer's Coordinating Center Uniform Data Set who converted to DLB at a subsequent visit. Prevalence of neuropsychiatric and motor symptoms were examined up to 5 years prior to DLB diagnosis. The sample included 116 participants clinically diagnosed with DLB and 348 age and sex-matched (1:3) Healthy Controls. Motor slowing was present in approximately 70% of participants 3 years prior to DLB diagnosis. In the prodromal phase, 50% of DLB participants demonstrated gait disorder, 70% had rigidity, 20% endorsed visual hallucinations, and over 50% of participants endorsed REM sleep behavior disorder. Apathy, depression, and anxiety were common prodromal neuropsychiatric symptoms. The presence of 1+ core clinical features of DLB in combination with apathy, depression, or anxiety resulted in the greatest AUC (0.815; 95% CI: 0.767, 0.865) for distinguishing HC from prodromal DLB 1 year prior to diagnosis. The presence of 2+ core clinical features was also accurate in differentiating between groups (AUC = 0.806; 95% CI: 0.756, 0.855). A wide range of motor, neuropsychiatric and other core clinical symptoms are common in prodromal DLB. A combination of core clinical features, neuropsychiatric symptoms and cognitive impairment can accurately differentiate DLB from normal aging prior to dementia onset.

Sections du résumé

BACKGROUND
Research criteria for prodromal dementia with Lewy bodies (DLB) were published in 2020, but little is known regarding prodromal DLB in clinical settings.
METHODS
We identified non-demented participants without neurodegenerative disease from the National Alzheimer's Coordinating Center Uniform Data Set who converted to DLB at a subsequent visit. Prevalence of neuropsychiatric and motor symptoms were examined up to 5 years prior to DLB diagnosis.
RESULTS
The sample included 116 participants clinically diagnosed with DLB and 348 age and sex-matched (1:3) Healthy Controls. Motor slowing was present in approximately 70% of participants 3 years prior to DLB diagnosis. In the prodromal phase, 50% of DLB participants demonstrated gait disorder, 70% had rigidity, 20% endorsed visual hallucinations, and over 50% of participants endorsed REM sleep behavior disorder. Apathy, depression, and anxiety were common prodromal neuropsychiatric symptoms. The presence of 1+ core clinical features of DLB in combination with apathy, depression, or anxiety resulted in the greatest AUC (0.815; 95% CI: 0.767, 0.865) for distinguishing HC from prodromal DLB 1 year prior to diagnosis. The presence of 2+ core clinical features was also accurate in differentiating between groups (AUC = 0.806; 95% CI: 0.756, 0.855).
CONCLUSION
A wide range of motor, neuropsychiatric and other core clinical symptoms are common in prodromal DLB. A combination of core clinical features, neuropsychiatric symptoms and cognitive impairment can accurately differentiate DLB from normal aging prior to dementia onset.

Identifiants

pubmed: 34114509
doi: 10.1177/08919887211023586
pmc: PMC9150711
mid: NIHMS1810482
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

527-534

Subventions

Organisme : NIA NIH HHS
ID : P50 AG005142
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG047266
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG010161
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG025688
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG005138
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG047366
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG010129
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG028383
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG033514
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG013854
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG053760
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG068128
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG010124
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG023501
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG005131
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG010133
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG016574
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG005146
Pays : United States
Organisme : NIA NIH HHS
ID : U24 AG072122
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG035982
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG008702
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG016976
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG008051
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG005681
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG013846
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG047270
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG017266
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG005136
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG049638
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG012300
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG062422
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG016573
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG005134
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG008017
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG005133
Pays : United States
Organisme : NIA NIH HHS
ID : K23 AG031861
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG019610
Pays : United States
Organisme : NIA NIH HHS
ID : P30 AG072947
Pays : United States

Références

J Gerontol. 1982 May;37(3):323-9
pubmed: 7069156
Neurobiol Aging. 2010 Oct;31(10):1805-13
pubmed: 19026468
Age Ageing. 1997 Sep;26(5):393-400
pubmed: 9351484
Br J Psychiatry. 2002 Mar;180:270-6
pubmed: 11872521
BJPsych Open. 2020 Jun 16;6(4):e61
pubmed: 32539875
Neurology. 2009 Oct 6;73(14):1127-33
pubmed: 19805729
Neurology. 2015 Feb 17;84(7):654-8
pubmed: 25609758
Neurology. 2020 Apr 28;94(17):743-755
pubmed: 32241955
Mov Disord. 2017 Nov;32(11):1640-1645
pubmed: 29063713
J Am Geriatr Soc. 2005 Apr;53(4):695-9
pubmed: 15817019
Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4):210-6
pubmed: 17132964
Trials. 2016 Oct 7;17(1):485
pubmed: 27717392
J Neural Transm (Vienna). 2016 Apr;123(4):431-8
pubmed: 26852137
Neurology. 2003 Oct 14;61(7):944-9
pubmed: 14557565
J Neurol Neurosurg Psychiatry. 2021 Feb;92(2):158-164
pubmed: 33268471
Neurology. 2016 Nov 29;87(22):2317-2323
pubmed: 27807186
Neurology. 2017 Jul 4;89(1):88-100
pubmed: 28592453
Lancet. 2015 Oct 24;386(10004):1683-97
pubmed: 26595642
J Alzheimers Dis. 2017;58(2):463-470
pubmed: 28453473
Mov Disord. 2018 May;33(5):839-843
pubmed: 29442392
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Alzheimers Dement. 2019 Jul;15(7):899-906
pubmed: 31175026
J Geriatr Psychiatry Neurol. 2016 Sep;29(5):249-53
pubmed: 27502299
Mov Disord. 2020 May;35(5):859-867
pubmed: 32048343
Neurology. 2016 Sep 6;87(10):1036-44
pubmed: 27488597
Mov Disord. 2015 Oct;30(12):1591-601
pubmed: 26474316
Dement Geriatr Cogn Disord. 2012;33(4):273-81
pubmed: 22722638
Mov Disord. 2013 May;28(5):597-604
pubmed: 23554107
Alzheimer Dis Assoc Disord. 2010 Oct-Dec;24(4):348-53
pubmed: 20592580
Alzheimers Dement. 2020 Mar;16(3):524-530
pubmed: 32043803
J Neuropsychiatry Clin Neurosci. 2000 Spring;12(2):233-9
pubmed: 11001602
Neurology. 2013 Dec 3;81(23):2032-8
pubmed: 24212390

Auteurs

Kathryn A Wyman-Chick (KA)

7126HealthPartners Center for Memory and Aging, Saint Paul, MN, USA.
51441HealthPartners Institute, Bloomington, MN, USA.

Lauren R O'Keefe (LR)

51441HealthPartners Institute, Bloomington, MN, USA.

Daniel Weintraub (D)

14640University of Pennsylvania School of Medicine, Philadelphia, PA, USA.
Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA.

Melissa J Armstrong (MJ)

12233University of Florida College of Medicine, Gainesville, FL, USA.
Fixel Institute for Neurologic Diseases, University of Florida, Gainesville, FL, USA.

Michael Rosenbloom (M)

7126HealthPartners Center for Memory and Aging, Saint Paul, MN, USA.
51441HealthPartners Institute, Bloomington, MN, USA.

Phillip K Martin (PK)

12251University of Kansas School of Medicine-Wichita, KS, USA.

Terry R Barclay (TR)

7126HealthPartners Center for Memory and Aging, Saint Paul, MN, USA.
51441HealthPartners Institute, Bloomington, MN, USA.

Matthew J Barrett (MJ)

6886Virginia Commonwealth University, Richmond, VA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH